In addition, only 14 cases reported pathological findings coming from concomitant neoplasms (small cell lung cancer, breast cancer and non-small cell lung cancer) in which amphiphysin-IgG was present in patients’ tumor tissues, which correlated with the patients’ antibody specificity (8, 9). This evidence concerns the gene AMPH and non-small cell lung carcinoma.